Cargando…
Clinical utility and impact of the use of the chromogenic vs one‐stage factor activity assays in haemophilia A and B
Treatment of haemophilia A/B patients comprises factor VIII (FVIII) or factor IX (FIX) concentrate replacement therapy, respectively. FVIII and FIX activity levels can be measured in clinical laboratories using one‐stage activated partial thromboplastin time (aPTT)‐based clotting or two‐stage chromo...
Autores principales: | Marlar, Richard A., Strandberg, Karin, Shima, Midori, Adcock, Dorothy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916414/ https://www.ncbi.nlm.nih.gov/pubmed/31606899 http://dx.doi.org/10.1111/ejh.13339 |
Ejemplares similares
-
The one‐stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non‐severe haemophilia A: Superiority or non‐inferiority?
por: Schütte, Lisette M., et al.
Publicado: (2020) -
Utility of the chromogenic and fluorogenic properties of benzofurazan for the assay of milnacipran in human urine and plasma
por: Mostafa, Islam M., et al.
Publicado: (2018) -
Analytical variation in factor VIII one‐stage and chromogenic assays: Experiences from the ECAT external quality assessment programme
por: van Moort, Iris, et al.
Publicado: (2018) -
Estimation of Nuwiq(®) (simoctocog alfa) activity using one‐stage and chromogenic assays—Results from an international comparative field study
por: Tiefenbacher, Stefan, et al.
Publicado: (2019) -
Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels
por: Hamedani, Nasim Shahidi, et al.
Publicado: (2022)